Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Momentum forward

<< Previous

Bullboard Posts

Next >>

Comment by canadafanon Nov 25, 2022 4:36pm

192 Views

Post# 35129106

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Momentum forward

All of your questions are answered on the most recent " investor presentation" on the corporate web site.
You seem to be looking for problems thst don't exist.
They have ample cash to near end of 2023.
Long before which ALL of the efficacy & need to use, questions will be answered.
There are 3-4 analysts covering Onc. They all have the same consensus , a partnership going into early 2023.
They could all be wrong.

To you Aware-1, bracelet bring wastes of time.
that too will be revealed. Some as early as next week ( Dec 7th)...

<< Previous

Bullboard Posts

Next >>

UniDoc brings AI-powered H3 Health Cube to Italy